信達生物(01801.HK)擬配售6800萬股配售股份 總籌23.75億港元
格隆匯9月12日丨信達生物(01801.HK)發佈公吿,2023年9月12日(交易時段前),公司與配售代理(即摩根士丹利亞洲有限公司)訂立配售協議,據此,配售代理同意作為配售代理行事,以作為公司的代理根據配售協議所載的條款並在其條件規限下,促使承配人(否則自行)以配售價購買6800萬股配售股份。配售股份的數目相當於該公吿日期已發行股份總數的約4.41%;及經擴大已發行股份總數的約4.22%。
過去幾年,公司業務經營持續取得重大進展,發展為中國領先的生物製藥公司。2023年上半年的最新業績顯示,公司收入表現強勁,經營效率提升,管線組合更多樣化,研發策略強化,風險管理及確保長期可持續發展的能力提升。為了公司未來發展,公司將可持續增長及全球創新作為其長期戰略目標。公司計劃長期持續發展其業務,並尋求成為全球首屈一指生物製藥公司的遠景。
假設全部配售股份獲悉數配售及認購,則配售事項所得款項總額預期約為23.746億港元,而所得款項淨額將約為23.568億港元。配售事項所得款項淨額約60%擬用於加速全球管線的多項優先臨牀前及臨牀計劃的研發,包括但不限於開展多區域臨牀試驗,以及建設全球基礎設施及設備;約30%用於開發、營銷及商業化IBI362(瑪仕度肽),一種治療糖尿病及肥胖的GLP-1R/GCGR雙激動劑及潛在臨牀階段最佳候選藥物。IBI362(瑪仕度肽)用於治療肥胖及糖尿病的臨牀3期研究於中國進行順利,後續計劃提交NDA申請;及約10%作一般及企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.